Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma

NCT00536913 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Budesonide/formoterol pMDI 40/2.25ug + spacer
DRUG: Budesonide/formoterol pMDI 40/2.25 ug

Sponsor

AstraZeneca